Heart Disease News and Research

Latest Heart Disease News and Research

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

Politico looks at a new fight brewing over Agent Orange and how it affects programs for Vietnam Veterans. "It's a world turned upside-down from decades ago when returning soldiers had to fight to get attention for deadly lymphomas linked to the herbicide. Now the frailties of men in their 60s — prostate cancer, diabetes, heart disease — lead the list of qualified Agent Orange disabilities, and the result has been an explosion in claims — and the government's liability.

31 Aug 2010

$Heparin enoxaparin may provide better outcomes than unfractionated heparin$

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Results from ATOLL, a phase 3 randomised trial comparing two anticoagulants in primary PCI for ST elevation MI, show that the low molecular weight heparin enoxaparin may provide better outcomes in such cases than the traditionally used unfractionated heparin.

30 Aug 2010

Nihon-Kohden granted exclusive rights to distribute Z-Medica's QuikClot line of hemostatic agents in Japan

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed an exclusive distribution agreement with Nihon-Kohden, Japan's leading manufacturer, developer and distributor of medical electronic equipment . The agreement allows Nihon-Kohden the exclusive right to distribute Z-Medica's QuikClot line of hemostatic agents to hospital, military and law enforcement markets throughout Japan. The companies have been working together since early 2009 to obtain regulatory approval.

From Medica Corporation 30 Aug 2010

MRI recordings at one fiftieth of a second

"Please hold absolutely still": This instruction is crucial for patients being examined by magnetic resonance imaging (MRI). It is the only way to obtain clear images for diagnosis. Up to now, it was therefore almost impossible to image moving organs using MRI. Max Planck researchers from G-ttingen have now succeeded in significantly reducing the time required for recording images - to just one fiftieth of a second.

30 Aug 2010

Canada hosts 13th World Congress On Pain

The Canadian Pain Society (CPS) eagerly welcomes leading pain experts from across Canada and around the globe to the 13th World Congress on Pain in Montreal, Quebec, from August 29 to September 2. Hosted by the International Association for the Study of Pain (IASP), more than 6,000 pain professionals will gather to share their thoughts, research and best treatment practices concerning this throbbing public health issue.

30 Aug 2010

Perfadex improves survival in lung tranplant patients: Study

A recently published study in The Journal of Heart and Lung Transplantation shows that the patients who are most seriously ill before lung tranplantation have better one-year survival when Perfadex is used as the preservation solution for donor lungs compared with UW solution. Furthermore, the patients who received lungs preserved in Perfadex ran a significantly lower risk of being affected by rejection reactions requiring treatment.

30 Aug 2010

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Positron Corporation is pleased to announce K. Lance Gould M.D. as the keynote speaker for their upcoming cardiac PET symposium, held at the American Society of Nuclear Cardiology annual meeting, September 23-26 in Philadelphia, PA.

30 Aug 2010

Patients with atherothrombosis are at increased risk of ischemic events: Study

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

30 Aug 2010

Royal Philips Electronics launches new iE33 xMATRIX cardiac ultrasound system

Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.

From Philips Healthcare 30 Aug 2010

Closing ceremony of heart transplant recipient's 700 km bicycle tour across Canada

Media representatives are invited to join us for the closing ceremony of heart transplant recipient Sylvain Bédard's bicycle tour, to take place at the Montreal Heart Institute (MHI). Dr. Michel Pellerin, the cardiac surgeon who performed the operation, will present him with an official MHI shirt as well as a bouquet of flowers to mark his accomplishment: a tour across Canada, 700 kilometres of which were done on bicycle.

30 Aug 2010

Patient Home Monitoring releases Reverse Take Over third quarter 2010 results

Patient Home Monitoring, a new company focused on in-home cardiology healthcare services, today released its post Reverse Take Over third quarter financial results, which primarily represent the period from the RTO on June 2, 2010 to June 30, 2010.

30 Aug 2010

Selective lowering of heart rate reduces risk of death and hospitalization: Study

The results of a major international study presented at the European Society of Cardiology Congress in Stockholm and published simultaneously in The Lancet show, for the first time, that selectively lowering heart rate with a novel medication, ivabradine, significantly reduces risk of death and hospitalization for patients with heart failure. This also resolves a longstanding debate about whether lowering heart rate itself can actually lower the risk of heart disease progression.

30 Aug 2010

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genzyme Corp. today confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash. The Genzyme board of directors met last night, unanimously affirmed its previous rejection of Sanofi's proposal, and instructed the company to send Sanofi the following response letter:

30 Aug 2010

Genetic variations in Y chromosome affect men's risk of coronary heart disease: Scientists

Scientists in the UK have shown that genetic variations in the Y chromosome affect a male's risk of coronary heart disease. It is well known that males have a higher incidence of coronary heart disease than females due, in part, to the Y chromosome they inherit from their fathers. To investigate the role of the Y chromosome further, a team from the University of Leicester carried out research to determine whether genetic variations in the Y-chromosome affect risk for males.

30 Aug 2010

MedCath to sell interest in Avera Heart Hospital of South Dakota to Avera McKennan

MedCath Corporation announced today it has entered into a definitive agreement to sell its subsidiary which is the indirect owner of a one-third ownership interest and management rights in Avera Heart Hospital of South Dakota to Avera McKennan. The transaction is expected to close in 45 to 90 days, subject to certain closing conditions.

30 Aug 2010

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

Results from the Alpha Omega Trial, a multicentre, placebo-controlled trial in men and women following myocardial infarction (MI), suggest that low doses of n-3 fatty acids given in the form of enriched margarines do not reduce the overall rate of major cardiovascular events.

30 Aug 2010

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

Results from a recent phase 2b clinical trial may provide a new approach to managing excess potassium levels in patients with heart failure and heart failure with chronic kidney disease.

30 Aug 2010

SHIFT study finds Ivabradine reduces heart failure risk

Ivabradine, a selective If inhibitor already investigated for its effects in coronary artery disease and left ventricular dysfunction, significantly lowers the risk of heart failure, according to results of the SHIFT study (Systolic Heart failure treatment with the If inhibitor ivabradine Trial).

30 Aug 2010

Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction

Results from the HEBE III study, a prospective, randomised, multicentre trial performed in seven centres in the Netherlands, suggest that the promising effects of erythropoieitin seen in previous smaller studies cannot be confirmed for the improvement of clinical outcome in patients with a first ST-elevation myocardial infarction.

30 Aug 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Nihon-Kohden granted exclusive rights to distribute Z-Medica's QuikClot line of hemostatic agents in Japan

MRI recordings at one fiftieth of a second

Canada hosts 13th World Congress On Pain

Perfadex improves survival in lung tranplant patients: Study

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Patients with atherothrombosis are at increased risk of ischemic events: Study

Royal Philips Electronics launches new iE33 xMATRIX cardiac ultrasound system

Closing ceremony of heart transplant recipient's 700 km bicycle tour across Canada

Patient Home Monitoring releases Reverse Take Over third quarter 2010 results

Selective lowering of heart rate reduces risk of death and hospitalization: Study

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genetic variations in Y chromosome affect men's risk of coronary heart disease: Scientists

MedCath to sell interest in Avera Heart Hospital of South Dakota to Avera McKennan

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

SHIFT study finds Ivabradine reduces heart failure risk

Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Heart Disease News and Research

Latest Heart Disease News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in